Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer

Sponsor
Changhai Hospital
Study ID
NCT07691593
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • HRS-4642+NALIRIFOX — DRUG
    HRS-4642+NALIRIFOX
  • HRS-4642+NALIRIFOX+Adebrelimab — DRUG
    HRS-4642+NALIRIFOX+Adebrelimab
  • HRS-4642+NALIRIFOX+Adebrelimab — DRUG
    HRS-4642+NALIRIFOX+Adebrelimab

Study Details

To evaluate the safety and efficacy of neoadjuvant HRS-4642 plus chemotherapy with or without adebrelimab in patients with pancreatic ductal adenocarcinoma.

Key Dates

First listed
Jul 9, 2026
Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1：HRS-4642+NALIRIFOX
  • Experimental: Arm 2：HRS-4642+NALIRIFOX+Adebrelimab（4 cycles of neoadjuvant therapy）
  • Experimental: Arm 3：HRS-4642+NALIRIFOX+Adebrelimab（6 cycles of neoadjuvant therapy）

Primary Outcome Measure

Adverse events (AEs) [ Time Frame: From the first drug administration to within 30 days or within 60 days after the last dose of adebrelimab for the last dose ]

Find similar trials

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials

Related Studies